1. Home
  2. PTCT vs GKOS Comparison

PTCT vs GKOS Comparison

Compare PTCT & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PTC Therapeutics Inc.

PTCT

PTC Therapeutics Inc.

HOLD

Current Price

$75.18

Market Cap

5.7B

Sector

Health Care

ML Signal

HOLD

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$126.04

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PTCT
GKOS
Founded
1998
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.7B
6.0B
IPO Year
2006
2015

Fundamental Metrics

Financial Performance
Metric
PTCT
GKOS
Price
$75.18
$126.04
Analyst Decision
Buy
Strong Buy
Analyst Count
17
12
Target Price
$80.65
$126.92
AVG Volume (30 Days)
1.0M
1.3M
Earning Date
05-07-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
264.48
N/A
EPS
N/A
N/A
Revenue
$264,734,000.00
$507,442,000.00
Revenue This Year
N/A
$23.32
Revenue Next Year
$17.70
$27.43
P/E Ratio
N/A
N/A
Revenue Growth
36.19
32.33
52 Week Low
$43.18
$73.16
52 Week High
$87.50
$148.11

Technical Indicators

Market Signals
Indicator
PTCT
GKOS
Relative Strength Index (RSI) 60.42 53.33
Support Level $73.41 $94.16
Resistance Level $79.67 $147.43
Average True Range (ATR) 2.59 7.18
MACD 0.43 1.01
Stochastic Oscillator 90.99 91.26

Price Performance

Historical Comparison
PTCT
GKOS

About PTCT PTC Therapeutics Inc.

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: